Zai Lab

Zai Lab Acquisitions (Net)

Acquisitions (Net) of Zai Lab (ZLAB) as of Oct 27, 2026.

Acquisitions (Net)

-USD

Last updated:

Acquisitions (Net) of Zai Lab is 2026 - USD. Acquisitions (Net) of Zai Lab was 2025 - USD. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zai Lab Stock analysis

What does Zai Lab do? Zai Lab Ltd, based in Pudong, China, is a biopharmaceutical company operating in the Health Care sector. It develops and commercializes innovative treatments for oncology, immunology, neuroscience, and infectious diseases. The company offers products such as Zejula for ovarian cancer, VYVGART for myasthenia gravis, NUZYRA for bacterial infections, Optune for brain tumors, Qinlock for gastrointestinal tumors, Xacduro for bacterial pneumonia, and Augtyro for lung cancer. Zai Lab collaborates with leading pharmaceutical firms including Pfizer and Amgen. Zai Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zai Lab stock

On Eulerpool you can find the complete historical development of Acquisitions (Net) Zai Lab since 2006 – with annual values, charts, and detailed analysis.

Net acquisitions represent the cash spent on acquiring other businesses, net of divestitures. Large acquisitions can transform a company's growth trajectory.

Acquisitions (Net)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Acquisitions (Net)'s Zai Lab historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Zai Lab

All Key Metrics — Zai Lab